WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory
Novo NordiskNovo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.

www.novonordisk.com

List of articles in category Novo Nordisk
Title Published Date
Novo Nordisk has proposed to acquire Ablynx for upto €30.50 per share in cash, consisting of €28.00 upfront and €2.50 in Contingent Value Rights 08 January 2018
Interim results of first-ever global survey show people with type 2 diabetes underestimate their cardiovascular risk 06 December 2017
New US study reveals key reasons why millions of people with obesity are not receiving adequate care 01 November 2017
IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes 29 September 2017
More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments 12 September 2017
Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events 28 August 2017
Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial 15 June 2017
Call for applications: 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award 07 June 2017
Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment 03 April 2017
Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre 30 January 2017
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Tahmeena

Business & Industry

  • Pfizer reports record full-year 2022 results
  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries

Research & Development

  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Novo Nordisk

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.